Operation Eyesight Universal Institute for Eye Cancer, LV Prasad Eye Institute, Hyderabad, India.
Semin Ophthalmol. 2022 Oct-Nov;37(7-8):813-819. doi: 10.1080/08820538.2022.2078165. Epub 2022 May 23.
Retinoblastoma (RB) is the most common intraocular malignancy in children. The diagnosis of RB is mainly based on clinical features and imaging characteristics. Prognosis is based on stage of disease and response to treatment. In salvaged globes, direct tumor biopsy for genetic analysis and prognostication is an absolute contraindication at this point of time for the fear of extraocular tumor spread. Currently, there is a search for surrogate markers to allow accurate diagnosis and for prognostication, to predict the chances of globe salvage in RB. Therefore, biofluids such as plasma or aqueous humor have been studied to detect circulating tumor DNA (ctDNA) or cell-free DNA (cfDNA), respectively, to allow for treatment decision making, monitoring treatment response, and prognostic counselling.
A search of electronic databases (PubMed, Google Scholar and MEDLINE) of all articles on liquid biopsy in retinoblastoma published in English was performed. The keywords used for the search included "retinoblastoma", "liquid biopsy", "aqueous humor" "circulating tumor cells", "cell-free DNA", "cfDNA", "circulating tumor DNA", "ctDNA", "tumor fraction", " mutation" and "SNCA". Additionally, historic articles on the advent of liquid biopsy in medicine were also reviewed. Pertinent cross-references from the studies were reviewed. Retrospective interventional and observational case series, observational case series, prospective cohort studies, reviews, case reports, surgical techniques, invited commentary and letters were included.
A total of 40 relevant articles were selected. Biomarkers in aqueous humor, serum and cerebrospinal fluid and their clinical applications are discussed.
Harvesting aqueous humor from eyes with retinoblastoma has been found safe and superior to blood for the detection of chromosomal changes. cfDNA from aqueous can be a surrogate marker to detect somatic copy number alterations and other genetic alterations in RB. ctDNA in plasma also has potential to help in diagnosis and prognosis of RB. Liquid biopsy in RB is an emerging topic, which could pave way for a better understanding of mechanisms for treatment response, resistance and recurrence in RB as well as possibly provide specific therapeutic targets to improve globe salvage.
视网膜母细胞瘤(RB)是儿童中最常见的眼内恶性肿瘤。RB 的诊断主要基于临床特征和影像学特征。预后基于疾病的分期和对治疗的反应。在挽救眼球的情况下,由于担心眼外肿瘤扩散,直接对肿瘤进行活检以进行遗传分析和预后判断目前是绝对禁忌。目前,正在寻找替代标志物,以实现准确诊断和预后,从而预测 RB 眼球挽救的机会。因此,已经研究了生物体液,如血浆或房水,以分别检测循环肿瘤 DNA(ctDNA)或无细胞 DNA(cfDNA),以用于治疗决策、监测治疗反应和预后咨询。
对发表在英文期刊上的所有关于视网膜母细胞瘤液体活检的电子数据库(PubMed、Google Scholar 和 MEDLINE)进行了搜索。用于搜索的关键词包括“视网膜母细胞瘤”、“液体活检”、“房水”、“循环肿瘤细胞”、“无细胞 DNA”、“cfDNA”、“循环肿瘤 DNA”、“ctDNA”、“肿瘤分数”、“突变”和“SNCA”。此外,还回顾了关于液体活检在医学中的出现的历史文章。还回顾了研究中的相关交叉引用。纳入了回顾性干预性和观察性病例系列、观察性病例系列、前瞻性队列研究、综述、病例报告、手术技术、特邀评论和信件。
共选择了 40 篇相关文章。讨论了房水、血清和脑脊液中的生物标志物及其临床应用。
从患有视网膜母细胞瘤的眼睛中采集房水已被发现是安全的,并且比血液更适合检测染色体变化。cfDNA 可作为替代标志物,用于检测 RB 中的体细胞拷贝数改变和其他遗传改变。血浆中的 ctDNA 也有可能有助于 RB 的诊断和预后。RB 中的液体活检是一个新兴话题,它可能为更好地了解 RB 治疗反应、耐药性和复发的机制铺平道路,并可能提供特定的治疗靶点,以提高眼球挽救率。